HUTCHMED DRC

Yahoo Finance • 9 days ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, April 28, 2026 featuring live webcast presentations from international co... Full story

Yahoo Finance • 23 days ago

Agriculture, Construction, & Mining Machinery Industry Research Report 2026: Market to Reach $1.64 Trillion by 2032 - How Electrification and Telematics are Transforming Design

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Agriculture, Construction, & Mining Machinery Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Agriculture, Construction, & Mining Machi... Full story

Yahoo Finance • last month

Should You Be Adding HUTCHMED (China) (LON:HCM) To Your Watchlist Today?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stor... Full story

Yahoo Finance • last month

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-7... Full story

Yahoo Finance • 2 months ago

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology... Full story

Yahoo Finance • 2 months ago

Hutchmed price target lowered to $21 from $22 at BofA

BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $21 from $22 and keeps a Buy rating on the shares. The firm says Hutchmed’s FY25 print “offered some positive steps forward after a weaker 1H25.” Directional... Full story

Yahoo Finance • 2 months ago

Intended Retirement of Independent Non-executive Director and changes of composition of board committees

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Mok Shu Kam, Tony has informed the Compan... Full story

Yahoo Finance • 2 months ago

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — — Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2026 (GLOBE N... Full story

Yahoo Finance • 3 months ago

HUTCHMED to Announce 2025 Final Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, Marc... Full story

Yahoo Finance • 4 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 — — Savolitinib has the potential to become the first selective MET inhibitor in China for MET-ampl... Full story

Yahoo Finance • 4 months ago

Hutchmed's NDA For Fanregratinib In Intrahepatic Cholangiocarcinoma Accepted In China

(RTTNews) - Hutchmed China Ltd. (HCM, HCM.L) announced Monday that the China National Medical Products Administration (NMPA) has accepted and granted priority review for New Drug Application or NDA for fanregratinib (HMPL-453) to treat adu... Full story

Yahoo Finance • 4 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

— NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison — HONG KONG and SHANGHAI and FLORHA... Full story

Yahoo Finance • 4 months ago

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 17, 2025 (... Full story

Yahoo Finance • 5 months ago

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Sec... Full story

Yahoo Finance • 5 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by... Full story

Yahoo Finance • 6 months ago

HUTCHMED Breaks Below 200-Day Moving Average - Notable for HCM

In trading on Friday, shares of HUTCHMED (China) Ltd (Symbol: HCM) crossed below their 200 day moving average of $17.19, changing hands as low as $17.15 per share. HUTCHMED (China) Ltd shares are currently trading off about 1.6% on the da... Full story

Yahoo Finance • 6 months ago

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference (“dbVIC”) held Novem... Full story

Yahoo Finance • 6 months ago

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SAFFRON, a global Phase III study... Full story

Yahoo Finance • 6 months ago

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising pr... Full story

Yahoo Finance • 6 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, November 04, 2025, featuring live webcast presentations from international... Full story